Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$1.97
+1.5%
$3.41
$1.75
$8.59
$177.93M2.431.90 million shs2.52 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.65
-1.4%
$27.53
$25.20
$40.37
$156.68B0.741.69 million shs32.48 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
+1.55%-7.08%-46.90%-63.25%-59.71%
Pfizer Inc. stock logo
PFE
Pfizer
-1.39%-6.43%-2.83%-1.71%-31.39%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
1.3231 of 5 stars
3.31.00.00.02.61.70.6
Pfizer Inc. stock logo
PFE
Pfizer
4.6155 of 5 stars
3.23.02.54.81.51.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
2.67
Moderate Buy$15.25674.11% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.40
Hold$35.8629.68% Upside

Current Analyst Ratings

Latest CRBU and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/4/2024
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$24.00 ➝ $9.00
6/3/2024
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Inline$13.00 ➝ $3.00
5/16/2024
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
5/13/2024
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$28.00 ➝ $29.00
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$33.00 ➝ $36.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/22/2024
Pfizer Inc. stock logo
PFE
Pfizer
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/19/2024
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$23.00 ➝ $24.00
(Data available from 6/13/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$34.48M5.16N/AN/A$4.17 per share0.47
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.68$2.93 per share9.43$15.81 per share1.75

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$102.07M-$1.45N/AN/AN/A-345.05%-33.42%-28.01%8/13/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B-$0.06N/A10.051.10-0.56%8.64%3.70%8/6/2024 (Estimated)

Latest CRBU and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024Q1 2024
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$0.39-$0.46-$0.07-$0.46$3.00 million$2.43 million
5/1/2024Q1 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.56$0.82+$0.26$1.09$13.87 billion$14.88 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.08%+2.57%N/A 1 Years

Latest CRBU and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/A
10.49
10.49
Pfizer Inc. stock logo
PFE
Pfizer
0.66
1.05
0.78

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
77.51%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
9.50%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
15890.32 million81.74 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.67 billion5.66 billionOptionable

CRBU and PFE Headlines

Recent News About These Companies

Pfizer (NYSE:PFE) Trading Down 1%
3 Hidden-Gem Value Stocks to Buy and Never Let Go
Pfizer: An Oversold Pharma Stock in Recovery
7 Recession-Proof Stocks to Buy Now for Peace of Mind
Pfizer (NYSE:PFE) Shares Up 0.4%
Pfizer (NYSE:PFE) Shares Down 1.7%
Pfizer (NYSE:PFE) Shares Down 0.9%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Caribou Biosciences logo

Caribou Biosciences

NASDAQ:CRBU
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.